Brian Park, PharmD

Drug Information Specialist https://www.cancertherapyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Multiple Myeloma

Sarclisa Plus Carfilzomib and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma

Brian Park, PharmD

April 2, 2021

The approval is supported by data from the multicenter, randomized, open-label phase 3 IKEMA trial.

Hematologic Cancers

Novel Biologic for Chemotherapy-Induced Neutropenia Submitted to FDA

Brian Park, PharmD

April 1, 2021

Ryzneuta, also known as F-627, is an investigational, recombinant fusion protein containing G-CSF at the amino terminal and human IgG2-Fc fragment at the carboxyl terminal.

Multiple Myeloma

Abecma Approved for Relapsed/Refractory Multiple Myeloma

Brian Park, PharmD

March 30, 2021

Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.

Gynecologic Cancer

Improved Overall Survival With Cemiplimab in Cervical Cancer Trial

Brian Park, PharmD

March 16, 2021

The phase 3 trial evaluated the efficacy and safety of cemiplimab in women 18 years of age and older with recurrent or metastatic cervical cancer, including those with either squamous cell carcinoma or adenocarcinoma.

Renal Cell Carcinoma

Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma

Brian Park, PharmD

March 12, 2021

The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.

Lymphoma

First CAR T-Cell Therapy Approved for Indolent Follicular Lymphoma

Brian Park, PharmD

April 1, 2021

The approval was based on data from the single-arm, open-label phase 2 ZUMA-5 study.

Bladder Cancer

Tecentriq Indication for Prior-Platinum Treated Bladder Cancer Withdrawn

Brian Park, PharmD

March 9, 2021

In 2016, the FDA granted accelerated approval to Tecentriq for prior-platinum treated metastatic urothelial carcinoma based on tumor response rate and duration of response.

Lung Cancer